M

MacroGenics
D

MGNX

1.60000
USD
-0.09
(-5.04%)
مفتوح الان
حجم التداول
4,312
الربح لكل سهم
-3
العائد الربحي
-
P/E
-2
حجم السوق
100,944,517
أصول ذات صلة
ABBV
ABBV
3.750
(1.99%)
191.900 USD
AZN
AZN
2.510
(3.49%)
74.380 USD
BMY
BMY
-0.580
(-1.22%)
46.925 USD
GILD
GILD
0.610
(0.54%)
113.620 USD
INCY
INCY
6.550
(9.33%)
76.760 USD
MRK
MRK
-2.890
(-3.44%)
80.700 USD
N
NKTR
-0.780
(-3.30%)
22.870 USD
PFE
PFE
-0.055
(-0.23%)
24.220 USD
المزيد
الأخبار المقالات

العنوان: MacroGenics

القطاع: Healthcare
الصناعة: Biotechnology
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.